Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.38 |
| ▸ | HBB | P68871 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 10/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15533745 | 0.82 | TP53 (0.53) | MEN1KMT2AKDM4EALDH1A1BRCA1 | |
| SCHEMBL15533805 | 0.79 | ALOX5 (0.51) | MEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL15534280 | 0.78 | KDM4E (0.63) | MEN1KMT2AKDM4EALDH1A1BRCA1 | |
| SCHEMBL21295547 | 0.78 | MAOB (0.43) | MEN1KMT2AKDM4EALDH1A1BRCA1 | |
| SCHEMBL1201346 | 0.76 | CYP3A4 (0.44) | MEN1KMT2AKDM4EALDH1A1BRCA1 | |
| SCHEMBL16659211 | 0.76 | ALDH1A1 (0.40) | MEN1KMT2AKDM4EALDH1A1BRCA1 | |
| SCHEMBL8364512 | 0.75 | MAOB (0.56) | MEN1KMT2AALDH1A1TAAR1TP53 | |
| SCHEMBL29716171 | 0.75 | KDM4E (0.44) | MEN1KMT2AKDM4EALDH1A1BRCA1 | |
| SCHEMBL22009627 | 0.75 | KDM4E (0.44) | MEN1KMT2AKDM4EALDH1A1BRCA1 | |
| SCHEMBL22009628 | 0.75 | MEN1 (0.47) | MEN1KMT2AKDM4EALDH1A1BRCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180461-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-11-23 | — | — | US | disclosed |
| EP-2852589-B1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2021-04-28 | — | — | EP | disclosed |
| US-20200172496-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY SRL (IT) | 2020-06-04 | — | — | US | disclosed |
| US-10611735-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-04-07 | — | — | US | disclosed |
| US-20190071405-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2019-03-07 | — | — | US | disclosed |
| US-10160730-B2 | Triazoles as KV3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-12-25 | — | — | US | disclosed |
| US-20160318882-A1 | TRIAZOLES AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2016-11-03 | — | — | US | disclosed |
| US-9422252-B2 | Triazoles as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-08-23 | — | — | US | disclosed |
| US-20150111910-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-04-23 | — | — | US | disclosed |
| EP-2852589-A1 | TRIAZOLES AS KV3 INHIBITORS | Autifony Therapeutics Limited (GB) | 2015-04-01 | — | — | EP | disclosed |
| WO-2013175215-A1 | TRIAZOLES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10611735-B2 | Triazoles as Kv3 inhibitors | KCNA3, KCNN3, KCNK3 | MEN1 2340/4885KMT2A 984/4885KDM4E 1261/4885 |
| US-20150111910-A1 | TRIAZOLES AS KV3 INHIBITORS | KCNA3, KCNN3, KCNK3 | MEN1 2340/4885KMT2A 984/4885KDM4E 1261/4885 |
| US-20190071405-A1 | TRIAZOLES AS KV3 INHIBITORS | KCNA3, KCNN3, KCNK3 | MEN1 2340/4885KMT2A 984/4885KDM4E 1261/4885 |
| US-20200172496-A1 | TRIAZOLES AS KV3 INHIBITORS | KCNA3, KCNN3, KCNK3 | MEN1 2340/4885KMT2A 984/4885KDM4E 1261/4885 |
| US-11180461-B2 | Triazoles as Kv3 inhibitors | KCNA3, KCNN3, KCNK3 | MEN1 2340/4885KMT2A 984/4885KDM4E 1261/4885 |
| US-10160730-B2 | Triazoles as KV3 inhibitors | KCNA3, KCNN3, KCNK3 | MEN1 2340/4885KMT2A 984/4885KDM4E 1261/4885 |
| US-20160318882-A1 | TRIAZOLES AS KV3 INHIBITORS | KCNA3, KCNN3, KCNK3 | MEN1 2340/4885KMT2A 984/4885KDM4E 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.